Abstract:Gut microbiota plays a significant role in the balance between health and disease. Akkermansia muciniphila is one of the intestinal bacteria and its specialization in mucin degradation makes it a key organism at the mucosal interface between the lumen and host cells. A. muciniphila is found inversely associated with obesity, diabetes, cardiometabolic diseases and low-grade inflammation. Oral administration of A. muciniphila reduces the symptoms of metabolic disease in mice. Therefore, A. muciniphila is a promising candidate for the treatment of diabetes and obesity. Here, we summarize the existing data on A. muciniphila and its role in diabetes and obesity, to provide insight into the intricate mechanisms of A. muciniphila regulation of the cross-talk between the host and gut microbiota, so as to provide ideas for further research on A. muciniphila bacteria and the development of new drugs for diabetes.